Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genentech, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2.
The names of the study interventions involved in this study are:
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has not approved T-DM1 for pre-operative use in breast cancer but it has been approved for other uses in breast cancer. The FDA has approved pertuzumab as a pre-operative treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T-DM1 and Pertuzumab | Experimental | T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| T-DM1 | Drug | Neoadjuvant treatment is for a total of 18 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Pathologic Complete Response (pCR) by HER2 Amplification Status Non-Heterogeneous | The rate of pCR is the percentage of participants with Residual Cancer Burden (RCB)=0 as defined by established guidelines (Symmans et al. JCO 2007; M.D Anderson http://www.mdanderson.org/breastcancer\_RCB). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Evaluate upon completion of breast surgery, up to approximately 24 weeks from study enrollment. |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Pathologic Complete Response (pCR) | The rate of pCR is the percentage of participants with Residual Cancer Burden (RCB)=0 as defined by established guidelines (Symmans et al. JCO 2007; M.D Anderson http://www.mdanderson.org/breastcancer\_RCB). | Evaluate upon completion of breast surgery, up to approximately 24 weeks from study enrollment. |
Not provided
Inclusion Criteria:
Patients must have HER2-positive Stage II or III histologically confirmed invasive carcinoma of the breast. A minimum tumor size of 2 cm determined by physical exam or imaging is required.
HER-2 positive, confirmed by central testing (Clarient labs): IHC 3+ and/or FISH positive based on one of the three following criteria:
Single-probe average HER2 copy number≥6.0 signals/cell OR
Dual-probe HER2/CEP17 <2.0 with an average HER2 copy number ≥6.0 signals/cell OR
Dual-probe HER2/CEP17 ratio ≥2.0
ER/PR determination is required.
Bilateral breast cancers are allowed if both cancers are HER2-positive.
Patients with multifocal or multicentric disease are eligible as long as one area meets eligibility criteria.
Breast imaging should include the ipsilateral axilla. For subjects with a clinically negative axilla, a sentinel lymph node biopsy will be performed either before or after preoperative therapy at the discretion of the subject's physicians. For subjects with a clinically positive axilla, a needle aspiration, core biopsy or SLN procedure will be performed to determine the presence of metastatic disease in the lymph nodes.
Men and women (with any menopausal status) ≥ 18 years of age
ECOG performance status 0 or 1
Required laboratory values:
Documentation of hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies is required: this includes hepatitis B surface antigen (HBsAg) and/or total hepatitis B core antibody (HBcAb) in addition to HCV antibody testing.
Only for patients who test positive for hep B/C virus: PTT/INR < ULN (institutional)
Left ventricular ejection fraction (LVEF) ≥ 55%
Premenopausal women must have a negative serum pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause.
Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of study treatment.
Potent CYP3A4 inhibitors, such as ketoconazole and erythromycin, should be avoided during the study treatment period with T-DM1.
Excessive alcohol intake should be avoided (occasional use is permitted).
Patients with a history of ipsilateral DCIS are eligible.
Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy.
Willing and able to sign informed consent.
Willing to provide tissue for research purposes.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Otto Metzger, MD | Dana-Farber Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States | ||
| Dana Farber Cancer Institute |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38300710 | Derived | Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, Lester SC, Bellon JR, Winer EP, Spellman PT, Krop IE, Polyak K. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. J Clin Invest. 2024 Feb 1;134(7):e176454. doi: 10.1172/JCI176454. |
Not provided
Not provided
Not provided
Patients were enrolled from January 2015 to January 2018.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | T-DM1 and Pertuzumab | T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
patients treated with at least one dose of T-DM1 and pertuzumab
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | T-DM1 and Pertuzumab | T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Rate of Pathologic Complete Response (pCR) by HER2 Amplification Status Non-Heterogeneous | The rate of pCR is the percentage of participants with Residual Cancer Burden (RCB)=0 as defined by established guidelines (Symmans et al. JCO 2007; M.D Anderson http://www.mdanderson.org/breastcancer\_RCB). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. | Patients treated with at least one dose of T-DM1 and Pertuzumab and evaluable (with invasive disease present on the research core biopsy for evaluation of HER-2 heterogeneity by central pathology evaluation). | Posted | Number | 95% Confidence Interval | percentage of participants | Evaluate upon completion of breast surgery, up to approximately 24 weeks from study enrollment. |
|
Adverse events are assessed every cycle of neoadjuvant therapy prior to surgery, up to approximately 18 weeks (6 cycles) from study enrollment.
Serious adverse events (AEs) were defined as events with treatment-attribution of possibly, probably or definitely and grade 3 or higher per CTCAEv4. All remaining events regardless of treatment attribution were classified as Other AEs. Maximum grade toxicity by type for a patient over time was calculated. No further data is available to specify classification of other beyond the general term.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | T-DM1 and Pertuzumab | T-DM1 via IV every 3 weeks for 6 doses and Pertuzumab loading dose via IV on Cycle 1 Day 1 followed by maintenance dose via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor T-DM1: Participants will receive Trastuzumab emtansine (T-DM1) by IV every 3 weeks for 6 doses; for a total of 18 weeks of treatment. Pertuzumab: Participants will receive a loading dose of pertuzumab by IV on Cycle 1 Day 1 followed by maintenance dose of pertuzumab by IV every 3 weeks for a total of 6 doses; for a total of 18 weeks of treatment. Excision of tumor/mastectomy: Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Project Manager | Dana-Farber Cancer Institute | 617-632-3500 | ctopm@dfci.harvard.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jul 28, 2017 | Mar 31, 2021 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000080044 | Ado-Trastuzumab Emtansine |
| C485206 | pertuzumab |
| D008408 | Mastectomy |
| ID | Term |
|---|---|
| D008453 | Maytansine |
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D047029 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pertuzumab | Drug | Neoadjuvant treatment is for a total of 18 weeks. |
|
|
| Excision of tumor/mastectomy | Procedure | Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy. |
|
| Hormone Receptor (HR) Status by HER2 Amplification Status | HR status classified by estrogen receptor (ER) and/or progesterone receptor (ER) positive versus ER negative and PR negative determined by immunohistochemical methods according to the local institution's standard protocol. | Day 0 (baseline/at study entry) |
| Median Disease-Free Survival | Disease-free survival (DFS) based on the Kaplan-Meier method is defined as the duration of time from study entry to the occurrence of the first of the following events: local/regional recurrence, contralateral invasive breast cancer, distant recurrence or death from any cause. In situ cancer is not included as DFS event. Participants alive without an event are censored at date of last disease assessment. | Post-surgery follow-up of disease and survival occurs every 6 months for 5 years and annually until year 10. |
| Median Overall Survival | Overall survival (OS) based on Kaplan-Meier methods is defined as the interval from the date of registration to death from any cause. Patients are censored at date last known alive. | Post-surgery follow-up of disease and survival occurs every 6 months for 5 years and annually until year 10. |
| Clinical Response Rate (Complete Response) | Clinical response rate was defined as the percentage of participants achieving complete response (CR) based on RECIST 1.1 criteria on treatment up to surgery. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
| Clinical Response Rate (Partial Response) | Clinical response rate was defined as the percentage of participants achieving partial response (PR) based on RECIST 1.1 criteria on treatment up to surgery. Per RECIST 1.1 for target lesions: PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
| Number of Participants With a Dose Reduction | Number of participants with ever having dose reduction on neoadjuvant therapy up to surgery. | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
| Treatment-Emergent Fatigue Rate | Treatment-emergent fatigue rate is the percentage of participants who experienced grade 1-2 fatigue based on the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 as reported on the adverse event case report form. CTCAE severity scale ranges from 0 (none) to 5 (death): Grade 1=mild and Grade 2=moderate. | Adverse events are assessed every cycle of neoadjuvant therapy prior to surgery, up to approximately 18 weeks (6 cycles) from study enrollment. |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| Tennessee Oncology/Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | United States |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Hormone Receptor Status | Estrogen Receptor (ER) and Progesterone Receptor (PR) status | Count of Participants | Participants |
|
| HER2 Amplification Status | Patients underwent two ultrasound-guided core biopsies from different geographic areas of the same tumor prior to treatment. Central pathology evaluation of intratumor heterogeneity of HER2 expression was assessed by fluorescence in situ hybridization (FISH). HER2 heterogeneity was defined following the College of American Pathologists and the United Kingdom guidelines. HER2 heterogeneity was defined as the existence of an area of tumor cells with HER2 amplification representing more than 5% but less than 50% of infiltrating tumor cells, or an area of tumor that tested HER2-negative by FISH. | Count of Participants | Participants |
|
| Clinical Stage | Defined as the clinical breast cancer stage at baseline. Stage is degree of cancer burden, including size of cancer and nodal involvement. Stage 1 is the least burden and stage 2 and 3 having increased burden. | Count of Participants | Participants |
|
| HER-2 results by IHC (central confirmation) | HER-2 results by IHC confirmed by central laboratory. HER-2 status by immunohistochemistry with 3+ indicating clear HER-2 protein overexpression and 2+ indicating an equivocal level of HER-2 expression. HER2: human epidermal growth factor receptor 2 | Count of Participants | Participants |
|
| Histologic Grade | Histologic grade is a measure of cancer differentiation. Grade 1 is well differentiated, grade 2 is moderate differentiated and grade 3 is poorly differentiated. | Count of Participants | Participants |
|
T-DM1 and Pertuzumab T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy. |
| OG001 | Non-Heterogeneous HER2 Amplification Status | T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy. |
|
|
|
| Secondary | Rate of Pathologic Complete Response (pCR) | The rate of pCR is the percentage of participants with Residual Cancer Burden (RCB)=0 as defined by established guidelines (Symmans et al. JCO 2007; M.D Anderson http://www.mdanderson.org/breastcancer\_RCB). | Patients treated with at least one dose of T-DM1 and Pertuzumab and evaluable (with invasive disease present on the research core biopsy for evaluation of HER-2 heterogeneity by central pathology evaluation). | Posted | Number | 95% Confidence Interval | percentage of participants | Evaluate upon completion of breast surgery, up to approximately 24 weeks from study enrollment. |
|
|
|
| Secondary | Hormone Receptor (HR) Status by HER2 Amplification Status | HR status classified by estrogen receptor (ER) and/or progesterone receptor (ER) positive versus ER negative and PR negative determined by immunohistochemical methods according to the local institution's standard protocol. | Patients treated with at least one dose of T-DM1 and Pertuzumab and evaluable (with invasive disease present on the research core biopsy for evaluation of HER-2 heterogeneity by central pathology evaluation). | Posted | Count of Participants | Participants | Day 0 (baseline/at study entry) |
|
|
|
| Secondary | Median Disease-Free Survival | Disease-free survival (DFS) based on the Kaplan-Meier method is defined as the duration of time from study entry to the occurrence of the first of the following events: local/regional recurrence, contralateral invasive breast cancer, distant recurrence or death from any cause. In situ cancer is not included as DFS event. Participants alive without an event are censored at date of last disease assessment. | Not Posted | Jan 2028 | Post-surgery follow-up of disease and survival occurs every 6 months for 5 years and annually until year 10. | Participants |
| Secondary | Median Overall Survival | Overall survival (OS) based on Kaplan-Meier methods is defined as the interval from the date of registration to death from any cause. Patients are censored at date last known alive. | Not Posted | Jan 2028 | Post-surgery follow-up of disease and survival occurs every 6 months for 5 years and annually until year 10. | Participants |
| Secondary | Clinical Response Rate (Complete Response) | Clinical response rate was defined as the percentage of participants achieving complete response (CR) based on RECIST 1.1 criteria on treatment up to surgery. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions | Posted | Count of Participants | Participants | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
|
|
|
| Secondary | Clinical Response Rate (Partial Response) | Clinical response rate was defined as the percentage of participants achieving partial response (PR) based on RECIST 1.1 criteria on treatment up to surgery. Per RECIST 1.1 for target lesions: PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. | Posted | Count of Participants | Participants | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
|
|
|
| Secondary | Number of Participants With a Dose Reduction | Number of participants with ever having dose reduction on neoadjuvant therapy up to surgery. | Patients treated with at least one dose of T-DM1 and Pertuzumab. | Posted | Count of Participants | Participants | Evaluate upon completion of neoadjuvant therapy, up to approximately 18 weeks from study enrollment. |
|
|
|
| Secondary | Treatment-Emergent Fatigue Rate | Treatment-emergent fatigue rate is the percentage of participants who experienced grade 1-2 fatigue based on the Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 as reported on the adverse event case report form. CTCAE severity scale ranges from 0 (none) to 5 (death): Grade 1=mild and Grade 2=moderate. | Patients treated with at least one dose of T-DM1 and Pertuzumab. | Posted | Number | 95% Confidence Interval | percentage of participants | Adverse events are assessed every cycle of neoadjuvant therapy prior to surgery, up to approximately 18 weeks (6 cycles) from study enrollment. |
|
|
|
| 0 |
| 163 |
| 11 |
| 163 |
| 162 |
| 163 |
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Fatigue | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Platelet count decreased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Hypokalemia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hyponatremia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Blood and lymphatic system disorders - Other, specify | Blood and lymphatic system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Mitral valve disease | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| Palpitations | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| Sinus tachycardia | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| Cardiac disorders - Other, specify | Cardiac disorders | CTCAE (4.0) | Systematic Assessment |
|
| Ear pain | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Middle ear inflammation | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hypothyroidism | Endocrine disorders | CTCAE (4.0) | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Chills | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Edema limbs | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Fatigue | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Fever | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Flu like symptoms | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Infusion related reaction | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Non-cardiac chest pain | General disorders and administration site conditions | CTCAE (4.0) | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dry skin | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Rash acneiform | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
Not provided
Not provided
| D017437 |
| Skin and Connective Tissue Diseases |
| Lactams, Macrocyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D000068878 | Trastuzumab |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D013514 | Surgical Procedures, Operative |